Fig 1.
Yearly frequency of most common (≥5% overall) investigator-assessed drug-related AEs after the start of deferasirox. *Reported as an AE by the investigator.
Yearly frequency of most common (≥5% overall) investigator-assessed drug-related AEs after the start of deferasirox. *Reported as an AE by the investigator.